Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2014-000178-20-FR
EUCTR2014-000178-20-FRActive, not recruitingPhase 1

Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients

Erasmus Medical Centre0 sites40 target enrollmentStarted: December 14, 2015Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
40
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
Male

Inclusion Criteria

  • •clinical relevant mutation in the MCT8 gene leading to the clinical phenotype of AHDS
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 5
  • •F.1.2 Adults (18-64 years) no
  • •F.1.2.1 Number of subjects for this age range 0
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •-Major illness or recent major surgery (within 4 weeks) unrelated to AHDS
  • •- Patients who are participating in ongoing RCTs of therapeutic interventions (including clinical trials of investigational medicinal products);
  • •- Patients that have any major contra-indication for Triac treatment (severe cardiac decompensation (NYHA 4), coronary insufficiency, severe cardiac arrhytmias, Galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption)

Investigators

Sponsor
Erasmus Medical Centre

Similar Trials

Active, not recruiting
Phase 1
Therapy of MCT8 patients with the thyroid hormone analog Triac.This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.
EUCTR2014-000178-20-BEErasmus Medical Centre40
Active, not recruiting
Phase 1
Therapy of MCT8 patients with the thyroid hormone analog Triac.This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.
EUCTR2014-000178-20-ITErasmus Medical Centre40
Completed
Phase 2
Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial.Allan-Herndon-Dudley SyndromeMCT8 patient100146991004373910010335
NL-OMON44458Erasmus MC, Universitair Medisch Centrum Rotterdam15
Active, not recruiting
Phase 1
Therapy of MCT8 patients with the thyroid hormone analog Triac.This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.
EUCTR2014-000178-20-DEErasmus Medical Centre40
Active, not recruiting
Phase 1
Therapy of MCT8 patients with the thyroid hormone analog Triac.This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.
EUCTR2014-000178-20-CZErasmus Medical Centre40